Skip to main content
SpringerLink
Log in

Differentielle Indikationen der neuroleptischen Akutbehandlung Schizophrener

  • Conference paper
Neuroleptika Rückschau 1952–1986, Künftige Entwicklungen

Part of the book series: Tropon-Symposium ((BAYERZNS,volume 2))

Zusammenfassung

Untersuchungen über differentielle Indikationen der neuroleptischen Akutbehandlung müssen von zwei Voraussetzungen ausgehen:

  • Schizophrenien sind eine Gruppe von Krankheitsbildern mit heterogener Ätiologie, Pathogenese, Symptomatik und Prognose.

  • Neuroleptika wirken diagnoseübergreifend auf nosologisch unspezifische Zielsyndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Angrist B, Rotrosen J, Gerhon S (1980) Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 72: 17–19

    Article  PubMed  CAS  Google Scholar 

  • Aubree JC, Lader MH (1980) High and very high dosage antipsychotics: A critical review. J Clin Psychiatry 41: 341–350

    Google Scholar 

  • Bobon DP, Gottfries CG (1974) Clinical physiognomy of thioxanthenes. Acta Psychiat Belg 74: 441–568

    Google Scholar 

  • Carpenter WT, Mc Glashan TH, Strauss JS (1977) The treatment of schizophrenia without drugs. An investigation of some current assumptions. Am J Psychiatry 134: 14–20

    Google Scholar 

  • Cole JO, Bonato R, Goldberg SC (1968) Non-specific factors in the drug therapy of schizo-phrenic patients. In: Rickels K (ed) Non-specific factors in drug therapy. Thomas, Spring-field, Ill.

    Google Scholar 

  • Crow TJ (1980) Molecular pathology of schizophrenia: more than one desease process? Br Med J 280: 66–68

    Article  PubMed  CAS  Google Scholar 

  • Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6: 70–87

    PubMed  CAS  Google Scholar 

  • Delini-Stula A (1986) Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics. Pharmacopsychiatria 19: 134–139

    Article  CAS  Google Scholar 

  • Donlon PT (1976) High dosage neuroleptic therapy. Int Pharmacopsychiat 11: 235–245

    CAS  Google Scholar 

  • Frith CD, Stevens M, Johnstone EC, Crow TF (1979) Skin conductance responsitivity during acute episodes of schizophrenics as a predictor of symptomatic improvement. Psychol Med 9: 101–106

    Article  PubMed  CAS  Google Scholar 

  • Galbrecht CR, Klett CJ (1968) Predicting response to phenothiazines: The right drug for the right patient. J Nerv Ment Dis 147: 173–183

    Google Scholar 

  • Gardos G (1974) Are antipsychotic drugs interchangeable? J Nerv Ment Dis 159: 343–348

    Article  PubMed  CAS  Google Scholar 

  • Gardos G, Cole JO, Orzack MH (1973) The importance of dosage in antipsychotic drug administration — A review of dose-response studies. Psychopharmacologia 29: 221–230

    Article  PubMed  CAS  Google Scholar 

  • Goldberg SC, Frosch WA, Drossman AK, Schooler NR, Johnson CF (1972) Prediction of response to phenothiazines in schizophrenia. A cross validation study. Arch Gen Psychiatry 26: 367–373

    Article  PubMed  CAS  Google Scholar 

  • Goldberg SC, Schooler NR, Mattson N (1967) Paranoid and withdrawal symptoms in schizophrenia. J Nerv Ment Dis 145: 158–162

    Article  PubMed  CAS  Google Scholar 

  • Heimann H (1977) Wirkung von Psychopharmaka und zugrundeliegende theoretische Vorstellungen. Allgemeine methodologische Probleme der klinischen Prüfung von Psychopharmaka. Pharmacopsychiatria 10: 119–129

    Article  CAS  Google Scholar 

  • Hollister LE (1973) Clinical use of psychotherapeutic drugs. Thomas, Springfield, Ill.

    Google Scholar 

  • Hollister LE, Overall JE, Bennet JL, Kimbell I, Shelton J (1967) Spezific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients. Clin Pharmacol Ther 8: 249–255

    PubMed  CAS  Google Scholar 

  • Hollister LE, Overall JE, Kimbell I, Pokorny A (1974) Specific indications for different classes of phenothiazines. Arch Gen Psychiatry 30: 94–99

    Article  PubMed  CAS  Google Scholar 

  • Hyttel J, Larsen J-J, Christensen AV, Amt J (1985) Receptorbinding profiles of neuroleptics. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia research and treatment. Psychopharmacology, Supp12. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Itil TM (1977) Quantitative und qualitative EEG in Schizophrenia. Schizophr Bull 3: 61–69

    PubMed  CAS  Google Scholar 

  • Judd LL, Goldstein MJ, Rodnick EH, Jackson NL (1973) Phenothiazine effects in good premorbid schizophrenics divided into paranoid-nonparanoid status. Arch Gen Psychiatry 29: 207–211

    Article  PubMed  CAS  Google Scholar 

  • Kane JM (1985) Antipsychotic drug side effects: Their relationship to dose. J Clin Psychiatry 46: 16–21

    PubMed  CAS  Google Scholar 

  • Kebabian JW, Caine DB (1979) Multiple receptors for dopamine. Nature 277: 93–96

    Article  PubMed  CAS  Google Scholar 

  • Klein DF, Rosen B (1973) Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic in patients. Arch Gen Psychiatry 29: 480–485

    Article  PubMed  CAS  Google Scholar 

  • Klett CJ, Moseley EC (1965) The right drug for the right patient. J Consul Clin Psychol 29: 546–551

    CAS  Google Scholar 

  • Lehmann E, Klieser E, Wöller W, Quadbeck H, Tegeler J, Heinrich K (1987) Experimentelle Prüfung der Wechselwirkung von Haloperidol und Schizophrenietyp. In: Heinrich K (Hrsg) Probleme der neuroleptischen Dosierung. Schattauer, Stuttgart

    Google Scholar 

  • Lehmann E, Quadbeck H, Tegeler J, Fararuni M, Heinrich K (1980) Wirkungsdifferenzen bei Hoch-und Standarddosierung von Fluphenazin-Decanoat in Abhängigkeit von Patienten-Merkmalen. Pharmacopsychiatria 13: 117–129

    Article  CAS  Google Scholar 

  • Losonczy MF, Song IS, Mhos HC, Small NA, Davidson M, Johns CA, Davis KL (1986) Correlates of lateral ventricular size in chronic schizophrenia 1: Behavioral and treatment response measures. Am J Psychiatry 143: 976–981

    Google Scholar 

  • Luchins EDJ, Lewine RJ, Meltzer HY (1984) Lateral ventricular size, psychopathology, and medication response in the psychoses. Biol Psychiatry 19: 29–44

    PubMed  CAS  Google Scholar 

  • Marder SR, Kammen DP van, Docherty JP, Rayner J, Bunney WE (1979) Predicting drug-free improvement in schizophrenic psychosis. Arch Gen Psychiatry 36: 1080–1085

    Article  PubMed  CAS  Google Scholar 

  • May PRA, Dencker SJ, Liberman RP, Hubbard JW, Midha KK (1985) Ein systematischer Ansatz zur Therapieresistenz schizophrener Erkrankungen. Vortragsmanuskript Int. Schizophrenie-Symposium, München-Haar

    Google Scholar 

  • May PRA, Goldberg SC (1978) Prediction of schizophrenic patients’ response to pharmacotherapy. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York

    Google Scholar 

  • Möller HJ, Kissling W, Zerssen D von (1983) Die prognostische Bedeutung des frühen Ansprechens schizophrener Patienten auf Neuroleptika für den weiteren stationären Behandlungsverlauf. Pharmacopsychiatria 16: 46–49

    Article  PubMed  Google Scholar 

  • Möller HJ, Kissling W, Maurach R, Schmid W, Doerr P, Pirke K, Zerssen D von (1981) Beziehungen zwischen Haloperidol-Serumspiegel, Prolactin-Serumspiegel, antipsychotischem Effekt und extrapyramidalen Begleitwirkungen. Pharmacopsychiatria 14: 27–34

    Google Scholar 

  • Müller P (1987) Neuroleptische Dosierung bei therapieresistenten Schizophrenien. In: Heinrich K (Hrsg) Probleme der neuroleptischen Dosierung. Schattauer, Stuttgart

    Google Scholar 

  • Murphy DL, Shiling DJ, Murray RM (1978) Psychoactive drug responder subgroups: Possible contributions to psychiatric classification. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York

    Google Scholar 

  • Nasrallah HY, Kuperman S, Hamra BJ (1983) Clinical differences between schizophrenic patients with and without large cerebral ventricles. J Clin Psychiatry 44: 407–409

    PubMed  CAS  Google Scholar 

  • Nedopil N, Pflieger R, Rüther E (1983) The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients. Pharmacopsychiatria 6: 195–200

    Google Scholar 

  • Nedopil N, Rüther E (1981) Initial improvement as predictor of outcome of neuroleptic therapy. Pharmacopsychiatria 14: 205–207

    Article  PubMed  CAS  Google Scholar 

  • National Institute of Mental Health, Psychopharmacology Research Branch Collaborative Study Group Short Term Improvement in Schizophrenia (1968) The contribution of background factors. Am J Psychiatry 124: 900–909

    Google Scholar 

  • Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137: 1518–1522

    PubMed  CAS  Google Scholar 

  • Putten T van, May PRA (1978) Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 35: 477–480

    Article  PubMed  Google Scholar 

  • Putten T van, May PRA, Marder SR, Wittmann LA (1981) Subjective response to antipsychiotic drugs. Arch Gen Psychiatry 38: 187–190

    Article  PubMed  Google Scholar 

  • Putten T van, May PRA, Marder SR (1984) Response to antipsychotic medication: the doctor’s and the consumer’s view. Am J Psychiatry 141: 16–19

    PubMed  Google Scholar 

  • Richelson E (1984) Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 45: 331–336

    PubMed  CAS  Google Scholar 

  • Schulz SC, Sinicrope P, Kishore P (1983) Treatment response and ventricular brain enlargement in young schizophrenic patients. Psychopharmacol Bull 19: 510–512

    PubMed  CAS  Google Scholar 

  • Seeman P (1982) Nomenclature of central and peripheral dopaminergic sites and receptors. Biochem Pharmacol 31: 2563–2568

    Article  PubMed  CAS  Google Scholar 

  • Singh MM, Kay SR (1979) Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis. Biol Psychiatry 14: 277–295

    PubMed  CAS  Google Scholar 

  • Spadoni AJ, Smith JA (1969) Milieu therapy in schizophrenia. Arch Gen Psychiatry 20: 547–551

    Article  PubMed  CAS  Google Scholar 

  • Sokoloff D, Martress MP, Delandre M, Schwartz JC, Protais P, Costentin J (1983) Two classes of dopamine receptors distinguishable by substituted benzamides. In: Ackenheil M, Matussek N (eds) Special aspects of psychopharmacology. Expansion Scientifique Francaise

    Google Scholar 

  • Tegeler J (1983) Dosierung und Verträglichkeit der Depot-und Langzeitneuroleptika. In: Pö1dinger W (Hrsg) Tegeler J 35, Tropon Köln

    Google Scholar 

  • Tegeler J, Lehmann E, Quadbeck H, Klieser E, Wöller W (1982) Experimenteller Vergleich niedriger und hoher Haloperidol-Dosen in der Behandlung akut schizophrener Patienten. Arzneimittelforsch 32 (II): 887–888

    Google Scholar 

  • Ungerstedt U, Herrera-Marschitz M, Stahle L, Tossman U, Zetterström T (1985) Functional classification of different dopamine receptors. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia research and treatment psychopharmacology, Suppl 2. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Weinberger TR, Bigelow LB, Kleinman JE (1980) Cerebral ventricular enlargement and poor response to treatment. Arch Gen Psychiatry 37: 11–13

    Article  PubMed  CAS  Google Scholar 

  • Woggon B (1980) Veränderungen der psychopathologischen Symptomatik während 20tägiger antidepressiver oder neuroleptischer Behandlung. Psychiatr Clin (Basel) 13: 150–164

    CAS  Google Scholar 

  • Woggon B (1983) Prognose der Psychopharmakotherapie. Enke, Stuttgart

    Google Scholar 

Download references

Authors
  1. J. Tegeler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 24, rue des Fossés Saint Jacques, F-75005, Paris, France

    Pierre Pichot

  2. Psychiatrische Klinik der Technischen Universität, Ismaninger Str. 22, D-8000, München 80, Deutschland

    Hans-Jürgen Möller

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Tegeler, J. (1987). Differentielle Indikationen der neuroleptischen Akutbehandlung Schizophrener. In: Pichot, P., Möller, HJ. (eds) Neuroleptika Rückschau 1952–1986, Künftige Entwicklungen. Tropon-Symposium, vol 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83188-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-83188-1_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-18197-2

  • Online ISBN: 978-3-642-83188-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation